Sun Pharma acquires US-based Merck spinoff Organon for $11.75 billion in an all-cash transaction.
The combined entity is projected to reach $12.4 billion in annual revenue, securing a top 25 global ranking.
The deal is highly leveraged, utilizing up to $9.75 billion in external debt to fund the buyout.
Sun Pharma gains critical strategic footing in global biosimilars and instant market penetration in China and Europe.
Read the full story on StartupFox